Goutham Madhadi

Why this site exists

When I started in this field, I didn't know where to look for anything. I could find the regulations, they're public, but regulations tell you what is required, not how it actually works in practice. I could find academic papers, compliance checklists, and expensive training courses that repeated the same surface-level content. What I couldn't find was someone explaining it the way a colleague would after a long inspection day. The real version. What actually fails, what FDA actually cares about in the room, what a "validated system" looks like in a company that's three months from a pre-approval inspection with a team of six.

I spent years collecting that knowledge the hard way. Sitting through inspections. Building programs from scratch. Inheriting broken ones. Watching what happens when an analyst doesn't understand why audit trails matter, or when a QA manager treats data integrity as a documentation exercise. I've been on both sides of that, the side where everything holds up and the side where it doesn't.

This site exists because that kind of knowledge shouldn't sit behind a paywall or live only in the heads of people who've been doing this long enough. It should be free, public, and written for the person who just started their first validation job and has no idea what they're supposed to be learning. Or the experienced professional who's good at their specific role but has never had to think about what an FDA investigator looks for in an audit trail review. Or the quality director who needs to build a data integrity program from scratch at a startup and has two months to get it inspection-ready.

The mission is simple: take what took years to learn in practice and make it available to anyone, for free, at whatever level they're starting from.

Background

I've spent 15+ years across pharma and biotech. Started in validation doing the work, writing protocols, running tests, building packages. Over time moved into designing the programs, then into leading them. Currently I lead data integrity and digital quality at a cell and gene therapy company, which is its own world, novel modalities, novel assays, a regulatory environment that's still being defined in real time, and an expectation that your data is BLA-ready even when you're still figuring out the process.

You learn more from watching things go wrong than from any training course. Programs that looked complete on paper but didn't hold up when someone actually stress-tested them. Systems that had every document in order but the people using them had no idea why any of it mattered. I've been in enough of those situations to know what the difference is between a quality program that works and one that just looks like it does.

Some of the interactive tools on this site came out of that same frustration: the commercial options for GxP data quality work tend to be expensive, not built by practitioners, and hard to adapt to the questions you actually need answered.

What I work on day to day

• FDA 21 CFR Part 11 compliance and audit trail integrity programs
• ALCOA+ data quality frameworks across GxP systems
• Computerized system validation and change control governance
• BLA data packages and regulatory submission readiness
• AI tools for compliance monitoring and anomaly detection in regulated systems
• Data governance: ownership models, metadata standards, system interoperability
• Inspection preparation and 483 response strategy

On the content here

Everything on this site is based on public regulatory sources: FDA guidance, EU GMP, ICH guidelines, PIC/S, MHRA. No proprietary internal information, no company-specific details, no confidential processes. All examples use fictional or generic contexts. The principles are real; the specifics are constructed to illustrate them.

I write at three levels, beginner, intermediate, and advanced, because the same topic needs to be explained differently depending on where you are. A first-year quality associate needs to understand what an audit trail is and why it matters. A validation specialist needs to know how to assess one. A program director needs to know how to build a review program that holds up under regulatory scrutiny and doesn't collapse when a key person leaves. Those are three different articles.

Nothing here is legal advice or regulatory consulting. It's practitioner knowledge, made public. Read it, apply professional judgment, check primary sources, and adapt it to your situation.

Get in touch

Email: goutham@madhadi.com
If you found something useful here, if something is wrong, or if there's a topic you think should be covered, I want to know.